Complication rate, cure rate, and long-term outcomes of microsurgery for intracranial dural arteriovenous fistulae: a multicenter series and systematic review.
Taku SugiyamaNaoki NakayamaSatoshi UshikoshiKen KazumataMichinari OkamotoMasaki ItoToshiya OsanaiYusuke ShimodaKazuki UchidaDaisuke ShimboYasuhiro ItoKatsuyuki AsaokaToshitaka NakamuraSatoshi KurodaKiyohiro HoukinPublished in: Neurosurgical review (2020)
Although microsurgery is an established treatment modality for intracranial dural arteriovenous fistula (dAVF), data regarding the perioperative complication rate, cure rate, and long-term outcomes remain scarce. The aims of this study were to describe our original experience with microsurgery, including the surgical complications and pitfalls, and conduct a systematic review of the relevant literature. A multicenter cohort of patients with dAVF treated by microsurgery was retrospectively assessed. In addition, the PubMed database was searched for published studies involving microsurgery for dAVF, and the complication rate, cure rate, and long-term outcomes were estimated. The total number of patients in our multicenter series and published articles was 553 (593 surgeries). The overall rates of transient complications, permanent complications, death, and incomplete treatment were 11.4, 4.0, 1.2, and 6.5%, respectively. A favorable outcome was achieved for 90.1% patients, even though almost half of the patients presented with intracranial hemorrhage. Of note, the incidence of recurrence was only one per 8241 patient-months of postoperative follow-up. Surgeries for anterior cranial fossa dAVF were associated with a lower complication rate, whereas those for tentorial dAVF were associated with higher complication and incomplete treatment rates. The complication and incomplete treatment rates were lower with simple disconnection of cortical venous drainage than with radical occlusion/resection of dural shunts. Our findings suggest that the cure rate, complication rates, and outcomes of microsurgery for dAVF are acceptable; thus, it could be a feasible second-line treatment option for dAVF. However, surgeons should be aware of the specific adverse events of microsurgery.
Keyphrases
- end stage renal disease
- systematic review
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- emergency department
- peritoneal dialysis
- type diabetes
- clinical trial
- patients undergoing
- cross sectional
- meta analyses
- acute kidney injury
- combination therapy
- randomized controlled trial
- patient reported outcomes
- big data
- replacement therapy
- brain injury
- optical coherence tomography
- patient reported
- subarachnoid hemorrhage